Cornerstone Planning LLC Invests $2.86 Million in Abbott Laboratories $ABT

Cornerstone Planning LLC purchased a new position in shares of Abbott Laboratories (NYSE:ABT) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 22,706 shares of the healthcare product maker’s stock, valued at approximately $2,858,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Freemont Management S.A. increased its holdings in shares of Abbott Laboratories by 197.2% in the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock valued at $1,341,000 after purchasing an additional 7,100 shares during the last quarter. PFA Pension Forsikringsaktieselskab acquired a new position in Abbott Laboratories during the fourth quarter worth $116,580,000. Thrivent Financial for Lutherans boosted its stake in Abbott Laboratories by 24.3% during the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock worth $30,931,000 after buying an additional 48,286 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab purchased a new stake in Abbott Laboratories in the 3rd quarter valued at $185,640,000. Finally, Net Worth Advisory Group acquired a new stake in shares of Abbott Laboratories in the 4th quarter worth $1,366,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analyst Ratings Changes

ABT has been the topic of several recent research reports. Bank of America lowered their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. The Goldman Sachs Group dropped their price target on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research note on Wednesday, May 27th. Royal Bank Of Canada reduced their target price on Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Argus decreased their price objective on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday, April 21st. Finally, Citigroup decreased their target price on Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $118.30.

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $88.48 on Friday. The stock’s 50-day simple moving average is $90.08 and its 200-day simple moving average is $106.60. The firm has a market capitalization of $154.12 billion, a PE ratio of 24.78, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $139.06. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same period in the prior year, the company posted $1.09 earnings per share. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities research analysts forecast that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be given a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.8%. Abbott Laboratories’s dividend payout ratio is 70.59%.

Insider Activity

In related news, CFO Philip P. Boudreau acquired 2,200 shares of Abbott Laboratories stock in a transaction on Thursday, April 23rd. The stock was purchased at an average cost of $91.50 per share, with a total value of $201,300.00. Following the purchase, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Daniel J. Starks bought 10,000 shares of the stock in a transaction on Monday, April 27th. The stock was bought at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the purchase, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their position. The SEC filing for this purchase provides additional information. 0.46% of the stock is currently owned by corporate insiders.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.